Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf cancer immunotherapies, cell therapies, and targeted biologic approaches designed to address hard-to-treat tumors. BioNTech also develops vaccine candidates and other immune-modulating treatments aimed at preventing or managing serious infectious diseases. Its work spans multiple platforms, including mRNA, protein-based therapies, and next-generation immunomodulators, reflecting a broad research and development base. BioNTech SE serves a central role in the biopharmaceutical market by advancing precision medicine approaches that combine molecular science with clinical development, supporting both preventative and therapeutic applications across global healthcare markets.
$93.67
+$2.48 (+2.72%)
Live · 11:53 PM
The business is unprofitable at the operating level (-22.32% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.3%, steady but not accelerating.
Negative free cash flow of -€293M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€2.81B
▲ +4.3% YoY
Net Income (TTM)
-€1.25B
▼ -70.8% YoY
Op. Margin
-27.67%
▼ -0.7pp YoY
ROIC
-2.59%
▼ -0.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€606M
▼ -19.8% YoY
Op. Cash Flow (TTM)
€706M
▼ -39.5% YoY
Net Debt
-€14.61B
Net Cash Position
Cash & Equiv.
€14.88B
3Y CAGR: -45.1%
Continue Research
BioNTech (BNTX) trades around a two-stage DCF intrinsic value of about €99.14 per share, so at €93.67 the stock looks around fair value (5.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BioNTech scores 16/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €99.14 per share for BNTX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €74.35. At today's €93.67, that puts the stock about 5.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
BioNTech scores 16 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -27.7% operating margin and a -2.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BNTX currently trades around its estimated intrinsic value and scores 16/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.